Clinical efficacy of tendon clearing technique combined with Zizhu ointment in the treatment of non-ischemic diabetic foot ulcers

注册号:

Registration number:

ITMCTR2025000230

最近更新日期:

Date of Last Refreshed on:

2025-02-08

注册时间:

Date of Registration:

2025-02-08

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

清筋术联合紫朱软膏治疗非缺血性糖尿病足溃疡的临床疗效

Public title:

Clinical efficacy of tendon clearing technique combined with Zizhu ointment in the treatment of non-ischemic diabetic foot ulcers

注册题目简写:

English Acronym:

研究课题的正式科学名称:

清筋术联合紫朱软膏治疗非缺血性糖尿病足溃疡的临床疗效

Scientific title:

Clinical efficacy of tendon clearing technique combined with Zizhu ointment in the treatment of non-ischemic diabetic foot ulcers

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙尧卿

研究负责人:

柳国斌

Applicant:

SUNYiuHing

Study leader:

LIUGuoBin

申请注册联系人电话:

Applicant telephone:

19852890537

研究负责人电话:

Study leader's telephone:

15800885533

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

527645466@qq.com

研究负责人电子邮件:

Study leader's E-mail:

drlguobin@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市浦东新区张衡路528号

研究负责人通讯地址:

上海市浦东新区张衡路528号

Applicant address:

No.528 Zhangheng Road Pudong New AreaShanghai

Study leader's address:

No.528 Zhangheng Road Pudong New AreaShanghai

申请注册联系人邮政编码:

Applicant postcode:

201203

研究负责人邮政编码:

Study leader's postcode:

201203

申请人所在单位:

上海中医药大学附属曙光医院

Applicant's institution:

Shuguang Hospital Affiliated Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2024160518801

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

上海中医药大学附属曙光医院伦理委员会

Name of the ethic committee:

EC of Shuguang Hospital Affiliated Shanghai University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024/10/9 0:00:00

伦理委员会联系人:

马俊坚

Contact Name of the ethic committee:

MAJunJian

伦理委员会联系地址:

上海市浦东新区张衡路528号

Contact Address of the ethic committee:

No.528 Zhangheng Road Pudong New AreaShanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 2025 6067

伦理委员会联系人邮箱:

Contact email of the ethic committee:

sgyyllwyh@126.com

研究实施负责(组长)单位:

上海中医药大学附属曙光医院

Primary sponsor:

Shuguang Hospital Affiliated Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市浦东新区张衡路528号

Primary sponsor's address:

No.528 Zhangheng Road Pudong New AreaShanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

浦东新区

Country:

CHINA

Province:

SHANGHAI

City:

SHANGHAI

单位(医院):

上海中医药大学附属曙光医院

具体地址:

上海市浦东新区张衡路528号

Institution
hospital:

Shuguang Hospital Affiliated Shanghai University of Traditional Chinese Medicine

Address:

No.528 Zhangheng Road Pudong New AreaShanghai

经费或物资来源:

自筹

Source(s) of funding:

self-financing

研究疾病:

糖尿病足溃疡

研究疾病代码:

E14.500x041

Target disease:

diabetic foot ulcers

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

本研究的主要目的是与清创治疗联合纳米银医用抗菌敷料比较,评估清筋术联合紫朱软膏治疗非缺血性糖尿病足溃疡患者的有效性和安全性。

Objectives of Study:

The main objective of this study was to evaluate the efficacy and safety of tendon clearing combined with Ziju ointment in the treatment of patients with non-ischemic diabetic foot ulcers in comparison with clearing treatment combined with nano-silver medical antimicrobial dressings.

药物成份或治疗方案详述:

治疗组:在治疗期期间,每日换药1次,连续8周。予以清筋术联合紫朱软膏外用。具体方法:局部创面外用双氧水,清洗干净后用碘伏对其周围进行消毒,在溃破和(或)肿胀选择最佳引流方向作为切开处,沿组织结构逐层分离,暴露坏死、变性的肌腱,探查溃疡边缘,清除坏死肌腱、组织、碎骨。据创面情况取适量的紫朱软膏摊于纱布,贴合创面,纱布覆盖,绷带缠缚包扎。 对照组:在治疗期期间,每日换药1次,连续8周。予以清创治疗联合纳米银医用抗菌敷料外用。具体方法:局部创面外用双氧水,清洗干净后用碘伏对其周围进行消毒,切开引流、清创,外用纳米银医用抗菌敷料填充创面,纱布覆盖,绷带缠缚包扎。

Description for medicine or protocol of treatment in detail:

Treatment group: during the treatment period the medication was changed once a day for 8 weeks. It was given clear tendon technique combined with topical application of Zi Zhu ointment. Specific methods: local trauma external hydrogen peroxide clean and disinfect its surrounding with iodine volts in the ulcerated and/or swollen choose the best drainage direction as the incision along the structure of the tissue layer by layer separation exposure of necrosis degeneration of tendon probe the edge of the ulcer remove necrotic tendon tissue broken bone. According to the wound condition appropriate amount of Zi Zhu ointment was taken and spread on gauze to close the wound which was covered with gauze and bandaged with bandage. Control group: during the treatment period change the medicine once a day for 8 weeks. It was given debridement treatment combined with nanosilver medical antimicrobial dressing for external use. Specific methods: local trauma external hydrogen peroxide cleaned with povidone-iodine to disinfect the surrounding incision and drainage debridement external nano-silver medical antibacterial dressings to fill the trauma gauze coverage bandage wrapping bandage.

纳入标准:

(1)符合上海市科委鉴定通过的《糖尿病足筋疽单病种质量控制标准》、《现代糖尿病诊断治疗学》中非缺血性糖尿病足诊断标准;符合中医证候诊断标准。 (2)年龄40~80岁; (3)患者踝肱指数在要求范围内:0.8<踝肱指数<1.3; (4)所有患者签署治疗知情同意书。

Inclusion criteria

(1) Comply with the quality control standard of single disease of diabetic foot gangrene and the diagnostic standard of non-ischemic diabetic foot in Modern Diabetes Diagnosis and Treatment approved by Shanghai Municipal Science and Technology Commission; and comply with the diagnostic standard of Chinese medicine evidence and symptoms. (2) The age is 40 to 80 years old; (3) Patients' ankle-brachial index is within the required range: 0.8 < ankle-brachial index < 1.3; (4) All patients signed an informed consent for treatment.

排除标准:

(1)年龄<40或>80岁; (2)缺血性糖尿病足溃疡者; (3)严重肝肾功能不全者,定义为:丙氨酸氨基转移酶(ALT)和/或天冬氨酸氨基转移酶(AST)≥2*本中心规定正常值上限(ULN),或血肌酐(Scr)>1.5*UNL; (4)恶性肿瘤或精神疾病患者; (5)外科或介入血管形成术治疗者; (6)入选前4周曾参加其它临床试验者。

Exclusion criteria:

(1) Age <40 or >80 years; (2) Those with ischemic diabetic foot ulcers; (3) Those with severe hepatic or renal insufficiency defined as alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥2* upper limit of normal (ULN) as defined by the Center or blood creatinine (Scr) >1.5*UNL; (4) Patients with malignant tumors or psychiatric disorders; (5) Those treated with surgical or interventional angioplasty; (6) Those who had participated in other clinical trials 4 weeks prior to enrollment.

研究实施时间:

Study execute time:

From 2024-10-08

To      2025-10-09

征募观察对象时间:

Recruiting time:

From 2024-10-09

To      2025-10-08

干预措施:

Interventions:

组别:

干预组

样本量:

53

Group:

Intervention

Sample size:

干预措施:

干预组:清筋术+紫朱软膏外用

干预措施代码:

Intervention:

Intervention groups:Tendon Cleansing + Zi Zhu Ointment for External Application;

Intervention code:

组别:

对照组

样本量:

53

Group:

Control

Sample size:

干预措施:

对照组:清创治疗+纳米银医用抗菌敷料外用

干预措施代码:

Intervention:

Control groups:Cleansing treatment + nano-silver medical antimicrobial dressing for external use

Intervention code:

样本总量 Total sample size : 106

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

上海

Country:

CHINA

Province:

SHANGHAI

City:

SHANGHAI

单位(医院):

上海中医药大学附属曙光医院

单位级别:

三级

Institution/hospital:

Shuguang Hospital Affiliated Shanghai University of Traditional Chinese Medicine

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

中医证候评分

指标类型:

次要指标

Outcome:

Chinese Medicine Symptom Score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

溃疡愈合率

指标类型:

主要指标

Outcome:

Ulcer healing rate

Type:

Primary indicator

测量时间点:

治疗前后

测量方法:

[(治疗前溃疡面积-治疗后溃疡面积)/治疗前溃疡面积]*100%

Measure time point of outcome:

before and after treatment

Measure method:

[(pre-treatment ulcer area - post-treatment ulcer area)/pre-treatment ulcer area]*100% = ulcer healing rate

指标中文名:

VAS评分

指标类型:

次要指标

Outcome:

VAS score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清炎症因子NLRP3、IL-1β、IL-18

指标类型:

次要指标

Outcome:

Serum inflammatory factors NLRP3 IL-1β IL-18

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 40
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

简单随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

Simple random number table

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Unshared

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理采用病例记录表记录

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and management is recorded using a case record form

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above